

## Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Ali	Moderator	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
DiNardo	Speaker	<ul style="list-style-type: none"> <li>AbbVie; Agios; Bristol Myers Squibb Company; Celgene; Foghorn; Gilead; Novartis; Takeda</li> <li>AbbVie; Agios; Astex; Bristol Myers Squibb Company; Calithera; Celgene; Cleave</li> <li>Notable Labs</li> </ul>	<ul style="list-style-type: none"> <li>Advisory Board, Consultant</li> <li>Research Funding</li> <li>Stock, Stock Options, Bonds</li> </ul>
Feldman	Moderator	<ul style="list-style-type: none"> <li>AbbVie, Acrotech Biopharma, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Epizyme, Genentech, Incyte Corporation, MorphoSys, Seattle Genetics</li> </ul>	<ul style="list-style-type: none"> <li>Advisory Board, Speaker</li> </ul>
Gertz	Speaker	<ul style="list-style-type: none"> <li>AbbVie, Celgene</li> <li>Akcea, Alnylym, Ambry Genetics, Amgen, Celgene, Janssen, Karyopharm, Prothena, Sanofi</li> <li>i3 Health</li> <li>Aurora Bio</li> <li>Ionis</li> <li>Pfizer</li> </ul>	<ul style="list-style-type: none"> <li>Data &amp; Safety Monitoring</li> <li>Honorarium</li> <li>Educational Materials</li> <li>Stock</li> <li>Advisory Board</li> <li>Honorarium to Institution</li> </ul>
Grivas	Speaker	<ul style="list-style-type: none"> <li>4D Pharma; Aadi Bioscience; Asieris Pharmaceuticals; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; BostonGene; Bristol Myers Squibb Company; CG Oncology; EMD Serono, Inc.; Fresenius Kabi; Gilead Sciences, Inc.; Guardant Health, Inc.; ImmunityBio; Infinity Pharmaceuticals; Janssen; Lucence; Merck Sharp &amp; Dohme GmbH; Pfizer, Inc.; PureTech Ventures; Roche; Seagen, Inc.; Silverback Therapeutics; Strata Oncology; UroGen Pharma</li> <li>ALX Oncology; Acrivon Therapeutics; Bavarian Nordic; Bristol Myers Squibb Company;</li> </ul>	<ul style="list-style-type: none"> <li>Advisory Board, Consultant</li> <li>Research Funding</li> </ul>

		Clovis Oncology; Debiopharm Group; G1 Therapeutics; Gilead Sciences, Inc.; GlaxoSmithKline; EMD Serono, Inc.; Mirati Therapeutics; Merck Sharp & Dohme GmbH; Pfizer, Inc.; QED Therapeutics	
<b>Hermel</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Hurvitz</b>	Speaker	<ul style="list-style-type: none"> <li>Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, Cytomx, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Eli Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics/Seagen, Zymeworks, Phoenix Molecular Designs, Ltd.</li> <li>Ideal Implant, ROMTech</li> </ul>	<ul style="list-style-type: none"> <li>Research Funding</li> <li>Stockholder</li> </ul>
<b>Kasthuri</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Kosty</b>	Course Director	<ul style="list-style-type: none"> <li>Phillips Medical</li> <li>Myovant</li> <li>Mirati</li> <li>Merck, Navaire</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Speaker</li> <li>Advisory Board</li> <li>Research Funding</li> </ul>
<b>Ma</b>	Speaker	<ul style="list-style-type: none"> <li>Takeda</li> </ul>	<ul style="list-style-type: none"> <li>Consultant, Research Funding</li> </ul>
<b>May</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>McGranahan</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Moll</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Nagler</b>	Moderator	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>O'Brien</b>	Speaker	<ul style="list-style-type: none"> <li>AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, AstraZeneca, Autolus, Bristol Myers Squibb, Celgene, DynaMed, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Johnson &amp; Johnson, Juno Therapeutics, MEI Pharma Inc., Merck &amp; Co., NOVA, Pfizer, Pharmacyclics, TG Therapeutics, Vaniyam Group LLC, Verastem Oncology, Vida Ventures Advisors, LLC</li> <li>Acerta, Alliance, BeiGene, Caribou Biosciences, Gilead, Kite, Loxo Oncology, Inc., Mustang, Nurix Therapeutics, Pfizer, Pharmacyclics, Regeneron, TG Therapeutics,</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Research Support</li> </ul>

<b>Reeves</b>	Speaker	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Sammons</b>	Speaker	<ul style="list-style-type: none"> <li>Astra Zeneca, BMS, Loxo Oncology, Sermonix, Seagen</li> <li>Astra Zeneca, Loxo Oncology, Gilead, Incyclix, Foundation Medicine, Pfizer, Relay Therapeutics, Novartis, Sermonix, Seagen</li> </ul>	<ul style="list-style-type: none"> <li>Research Funding</li> <li>Advisory Board</li> </ul>
<b>Short</b>	Speaker	<ul style="list-style-type: none"> <li>Astellas, Stemline Therapeutics, Takeda</li> <li>Amgen, Astellas, BeiGene, Pfizer, Sanofi</li> </ul>	<ul style="list-style-type: none"> <li>Research Funding</li> <li>Consultant, Honoraria</li> </ul>
<b>Warkentin</b>	Speaker	<ul style="list-style-type: none"> <li>Aspen Global, Bayer, CSL Behring, Ergomed, and Octapharma</li> <li>Alexion</li> <li>Instrumentation Laboratory</li> <li>Informa (Taylor &amp; Francis)</li> </ul>	<ul style="list-style-type: none"> <li>Consultant</li> <li>Speaker</li> <li>Research Funding</li> <li>Royalties</li> </ul>
<b>Weitz</b>	Speaker	<ul style="list-style-type: none"> <li>Alexion Pharmaceuticals; Apellis Pharmaceuticals; Sanofi Pharmaceuticals</li> <li>Alexion Pharmaceuticals; Apellis Pharmaceuticals</li> </ul>	<ul style="list-style-type: none"> <li>Consultant, Advisory Board</li> <li>Speakers Bureau</li> </ul>
<b>CME Committee</b>	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>
<b>Scripps Conference Services &amp; CME</b>	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> <li>None</li> </ul>	<ul style="list-style-type: none"> <li>N/A</li> </ul>

### Glossary of Terms

#### Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit [www.accme.org/standards](http://www.accme.org/standards).

#### Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.